Hypothesis-driven clinical studies

This survey aims to gather clinical follow-up data for our hypothesis-driven studies, focusing on real-world patients profiled with Canine CGP and treated with genomics-based therapy

Patient Information

Pet Name

First

Last

Pet Date of Birth (DOB)

VetOmics ID

e.g. VOC25020099

Patient Treatment History

Site where cancer is present: Documented

Site where cancer is present: Suspected

What was the treatment(s) for the patients?

Surgery
Conventional (non-targeted) chemotherapy. This includes both high- and low-dose (metronomic) chemotherapy.
Radiation Therapy
Targeted Therapy (e.g. Toceranib, Rapamycin, Trametinib)
Immunotherapy (e.g. gilvetmab, melanoma vaccine, torigen vaccine)
Other therapies (e.g. electrochemotherapy)
OTHER

Initial treatment is meant to include any therapy (or group of therapies) given until the first disease progression was noted.

If "OTHER", please specify

Generally speaking, would you consider the patient was given the standard of care (SOC) for this disease?

Yes, I would consider the treatments that have been performed SOC
No, I would not consider the treatments that have been performed SOC
Unknown/Not applicable

Was treatment given PRIOR TO VetOmics test and genomics-guided therapy?

Yes
No

The following questions apply to treatment received PRIOR TO VetOmics test and genomics-guided therapy

What was the FIRST treatment given before VetOmics test?

When was the treatment started?

What was the best response?

Did the cancer progress after this treatment?

Yes
No
Not evaluated yet

When was progression documented?

Sites of progression (check all that apply)

If "OTHER", please specify

Was additional (SECOND) treatment given prior to VetOmics test?

Yes
No

What was the 2nd treatment given before VetOmics test?

When was the 2nd treatment started?

What was the best response of 2nd treatment?

Did the cancer progress after the 2nd treatment?

Yes
No
Not evaluated yet

When was progression documented after the 2nd treatment?

Sites of progression (check all that apply)

If "OTHER", please specify

Was additional (THIRD) treatment given prior to VetOmics test?

Yes
No

What was the 3rd treatment given before VetOmics test?

When was the 3rd treatment started?

What was the best response of 3rd treatment?

Did the cancer progress after 3rd treatment?

Yes
No
Not evaluated yet

When was progression documented after the 3rd treatment?

Sites of progression after 3rd treatment (check all that apply)

If "OTHER", please specify (copy)

Any additional therapy PRIOR TO VetOmics test: please provide the start date(s) (MM/DD/YYYY), dosing and schedule, following the therapy name

e.g. Doxorubicin, 12/18/2022, IV

Was the patient treated based on VetOmics test and genomics-guided therapy?

Yes
No

What was the reason for not treating the patient based on VetOmics test and genomics-guided therapy?

If "OTHER", please specify

The following questions apply to Genomics-Guided Therapy recommended by VetOmics test

test progression the

Genomics-guided therapy: Under what condition was genomics-guided therapy administered?

First line therapy
Adjuvant therapy
Follow-up therapy after failure to respond to previous treatment(s)
OTHER

If "OTHER", please specify

What was the FIRST genomics-guided therapy or combination used?

If "OTHER", please specify

When was the 1st genomics-guided treatment started?

What was the best response?

Did the cancer progress after the 1st genomics-guided therapy?

Yes
No
Not evaluated yet

When was progression documented?

Sites of progression (check all that apply)

If "OTHER", please specify

Was additional (SECOND) genomics-guided therapy given?

Yes
No

What was the SECOND genomics-guided therapy or combination used?

If "OTHER", please specify

When was the 2nd genomics-guided therapy started?

What was the best response?

Did the cancer progress after the 2nd genomics-guided therapy?

Yes
No
Not evaluated yet

When was progression documented?

Sites of progression (check all that apply)

If "OTHER", please specify

Was additional (THIRD) genomics-guided therapy given?

Yes
No

What was the THIRD genomics-guided therapy or combination used?

If "OTHER", please specify

When was the 3rd genomics-guided therapy started?

What was the best response?

Did the cancer progress after the 3rd genomics-guided therapy?

Yes
No
Not evaluated yet

When was progression documented?

Sites of progression (check all that apply)

If "OTHER", please specify

Any additional genomics-guided therapy based on VetOmics recommendation: please provide the start date(s) (MM/DD/YYYY), dosing and schedule, following the therapy name

e.g. gilvetmab, 11/06/2023, 10 mg/kg, IV over 30 min

Any additional therapy and progression AFTER VetOmics-recommended genomics-guided therapy?

Please list and describe the therapy, start date (MM/DD/YYYY), duration, best response, and progression date (MM/DD/YYYY) for each treatment. e.g. eletrochemotherapy, start date: 6/23/2023, complete response for 6 month, progression date: 9/30/2023

Patient Current Status

Alive or Deceased

Alive
Deceased
Lost to follow-up (LTFU)

Alive: Date of last visit

Alive: Date of last contact

If any, please list the last time you were in touch with the client after the last visit

Lost to follow-up (LTFU): Date of last visit

Lost to follow-up (LTFU): Date of last contact

If any, please list the last time you were in touch with the client after the last visit

Deceased: Date of death

Type of death

Natural death
Euthanasia
Unknown

Cause of death

Related to cancer
Unrelated to cancer
Unknown

Cause of euthanasia

Related to cancer
Unrelated to cancer
Unknown

Hypothesis-driven clinical studies

Patient Information

Patient Treatment History

The following questions apply to treatment received PRIOR TO VetOmics test and genomics-guided therapy

The following questions apply to Genomics-Guided Therapy recommended by VetOmics test

Patient Current Status

Thank you for your time! We look forward to supporting you and your patient on this journey.